Early Study Shows HCV Vaccine Works
November 4, 2010
Preliminary data show an experimental therapeutic vaccine against hepatitis C virus boosted response rates by 12 percent compared with standard HCV treatment of ribavirin and pegylated interferon, researchers reported at the annual meeting of the American Association for the Study of Liver Diseases in Boston.
Study patients randomized to receive the vaccine were given five weekly doses of GI-5005, delivered subcutaneously, followed by two monthly doses. They then received the vaccine on a monthly basis along with standard treatment. The control group of 65 participants received only standard treatment. In both groups, treatment-naive patients were treated for 48 weeks, while previous nonresponders received 72 weeks of treatment.
GI-5005 yielded a 47 percent response rate overall, compared with 35 percent for standard care (P=0.037). Each study arm experienced a 13 percent discontinuation rate due to side effects.
Session moderator Douglas LaBrecque, MD, of the University of Iowa-Iowa City, said a "benign" therapeutic vaccine against HCV could be advantageous, especially "if you could eliminate some of the other medications, either interferon or the small molecules, which have their own side effects." However, acknowledging the study's small size and preliminary data, he added, "all you can say is that it wasn't a total failure."
11.02.2010; Michael Smith
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)